@article{085478803ca049458b8d947f2a0a8e52,
title = "Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial",
keywords = "breast cancer, CDK inhibitor, Ribociclib, Endocrine therapy, De novo advanced breast cancer, Hormon receptor positive",
author = "Joyce O{\textquoteright}shaughnessy and Katarina Petrakova and Sonke, {Gabe S.} and Pierfranco Conte and Arteaga, {Carlos L.} and Cameron, {David A.} and Hart, {Lowell L.} and Cristian Villanueva and Erik Jakobsen and Beck, {Joseph T.} and Deborah Lindquist and Farida Souami and Shoubhik Mondal and Caroline Germa and Hortobagyi, {Gabriel N.}",
year = "2017",
month = nov,
day = "21",
doi = "10.1007/s10549-017-4518-8",
language = "English",
journal = "Breast cancer research and treatment",
issn = "0167-6806",
publisher = "Springer",
}